A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC oleh Kenji Morimoto, MD, PhD, Ryo Sawada, MD, Tadaaki Yamada, MD, PhD, Koichi Azuma, MD, PhD, Kentaro Ito, MD, Yasuhiro Goto, MD, PhD, Hideharu Kimura, MD, PhD, Taishi Harada, MD, Shinsuke Shiotsu, MD, Nobuyo Tamiya, MD, PhD, Yusuke Chihara, MD, PhD, Takayuki Takeda, MD, PhD, Osamu Hiranuma, MD, Isao Hasegawa, MD, PhD, Yoshie Morimoto, MD, PhD, Masahiro Iwasaku, MD, PhD, Shinsaku Tokuda, MD, PhD, Koichi Takayama, MD, PhD